MX364207B - Inhibidores de agrecanasa. - Google Patents
Inhibidores de agrecanasa.Info
- Publication number
- MX364207B MX364207B MX2015005297A MX2015005297A MX364207B MX 364207 B MX364207 B MX 364207B MX 2015005297 A MX2015005297 A MX 2015005297A MX 2015005297 A MX2015005297 A MX 2015005297A MX 364207 B MX364207 B MX 364207B
- Authority
- MX
- Mexico
- Prior art keywords
- aggrecanase inhibitors
- aggrecanase
- inhibitors
- cyclopropyl
- intermediates
- Prior art date
Links
- 108010003059 aggrecanase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona compuestos que tienen la fórmula: en donde R1 se selecciona de metilo, etilo, propilo, ciclopropilo, y dimetilo, o una sal del mismo farmacéuticamente aceptable, junto con métodos y productos intermediarios para su preparación, y usos de los mismos. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718965P | 2012-10-26 | 2012-10-26 | |
| PCT/US2013/065591 WO2014066151A1 (en) | 2012-10-26 | 2013-10-18 | Aggrecanase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005297A MX2015005297A (es) | 2015-07-17 |
| MX364207B true MX364207B (es) | 2019-04-16 |
Family
ID=49515523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005297A MX364207B (es) | 2012-10-26 | 2013-10-18 | Inhibidores de agrecanasa. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9206139B2 (es) |
| EP (1) | EP2912021B1 (es) |
| JP (1) | JP6251279B2 (es) |
| KR (1) | KR101689983B1 (es) |
| CN (1) | CN104755464B (es) |
| AR (1) | AR092971A1 (es) |
| AU (1) | AU2013334989B2 (es) |
| BR (1) | BR112015009032B1 (es) |
| CA (1) | CA2886526C (es) |
| DK (1) | DK2912021T3 (es) |
| EA (1) | EA026037B1 (es) |
| ES (1) | ES2645970T3 (es) |
| HU (1) | HUE034616T2 (es) |
| MX (1) | MX364207B (es) |
| NZ (1) | NZ706772A (es) |
| PL (1) | PL2912021T3 (es) |
| PT (1) | PT2912021T (es) |
| TW (1) | TWI620738B (es) |
| WO (1) | WO2014066151A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6648127B2 (ja) | 2014-10-16 | 2020-02-14 | モンサント テクノロジー エルエルシー | 鱗翅類活性Ｃｒｙ１Ｄａ１アミノ酸配列変異体タンパク質 |
| JO3501B1 (ar) * | 2014-12-22 | 2020-07-05 | Servier Lab | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) |
| GB201610055D0 (en) * | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| GB201610056D0 (en) | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| WO2021011720A2 (en) * | 2019-07-18 | 2021-01-21 | Avidence Therapeutics, Inc. | Anti-osteoarthritis compounds and related compositions and methods |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
| WO2021214637A1 (en) * | 2020-04-20 | 2021-10-28 | St. Jude Children's Research Hospital | Composition and methods for treating respiratory diseases |
| WO2022007866A1 (zh) * | 2020-07-09 | 2022-01-13 | 深圳信立泰药业股份有限公司 | 并三环类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004535411A (ja) * | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物 |
| SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| JP2008546843A (ja) * | 2005-06-27 | 2008-12-25 | アムゲン インコーポレイティッド | 抗炎症性アリールニトリル化合物 |
| UA94412C2 (en) * | 2005-07-11 | 2011-05-10 | Уайет | Glutamate aggrecanase inhibitors |
| PE20071240A1 (es) * | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
-
2013
- 2013-10-10 AR ARP130103679A patent/AR092971A1/es active IP Right Grant
- 2013-10-15 TW TW102137198A patent/TWI620738B/zh active
- 2013-10-18 US US14/422,018 patent/US9206139B2/en active Active
- 2013-10-18 EA EA201590621A patent/EA026037B1/ru not_active IP Right Cessation
- 2013-10-18 CN CN201380055719.9A patent/CN104755464B/zh active Active
- 2013-10-18 PL PL13785745T patent/PL2912021T3/pl unknown
- 2013-10-18 WO PCT/US2013/065591 patent/WO2014066151A1/en not_active Ceased
- 2013-10-18 MX MX2015005297A patent/MX364207B/es active IP Right Grant
- 2013-10-18 EP EP13785745.4A patent/EP2912021B1/en active Active
- 2013-10-18 ES ES13785745.4T patent/ES2645970T3/es active Active
- 2013-10-18 CA CA2886526A patent/CA2886526C/en active Active
- 2013-10-18 JP JP2015539672A patent/JP6251279B2/ja active Active
- 2013-10-18 DK DK13785745.4T patent/DK2912021T3/en active
- 2013-10-18 AU AU2013334989A patent/AU2013334989B2/en active Active
- 2013-10-18 NZ NZ706772A patent/NZ706772A/en unknown
- 2013-10-18 HU HUE13785745A patent/HUE034616T2/en unknown
- 2013-10-18 BR BR112015009032-0A patent/BR112015009032B1/pt active IP Right Grant
- 2013-10-18 KR KR1020157010390A patent/KR101689983B1/ko active Active
- 2013-10-18 PT PT137857454T patent/PT2912021T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014066151A1 (en) | 2014-05-01 |
| NZ706772A (en) | 2018-05-25 |
| EP2912021B1 (en) | 2017-08-16 |
| EA026037B1 (ru) | 2017-02-28 |
| US20150218107A1 (en) | 2015-08-06 |
| CN104755464B (zh) | 2017-03-29 |
| CA2886526C (en) | 2018-03-27 |
| EA201590621A1 (ru) | 2015-07-30 |
| AU2013334989A1 (en) | 2015-04-23 |
| ES2645970T3 (es) | 2017-12-11 |
| CN104755464A (zh) | 2015-07-01 |
| EP2912021A1 (en) | 2015-09-02 |
| CA2886526A1 (en) | 2014-05-01 |
| AR092971A1 (es) | 2015-05-06 |
| PT2912021T (pt) | 2017-11-14 |
| KR101689983B1 (ko) | 2016-12-26 |
| TW201427955A (zh) | 2014-07-16 |
| PL2912021T3 (pl) | 2018-01-31 |
| JP2015535248A (ja) | 2015-12-10 |
| HUE034616T2 (en) | 2018-02-28 |
| BR112015009032A2 (pt) | 2017-07-04 |
| TWI620738B (zh) | 2018-04-11 |
| HK1211927A1 (en) | 2016-06-03 |
| JP6251279B2 (ja) | 2017-12-20 |
| US9206139B2 (en) | 2015-12-08 |
| KR20150058480A (ko) | 2015-05-28 |
| BR112015009032B1 (pt) | 2022-06-28 |
| DK2912021T3 (en) | 2017-10-02 |
| MX2015005297A (es) | 2015-07-17 |
| AU2013334989B2 (en) | 2016-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| PH12016500169A1 (en) | Polymorph of syk inhibitors | |
| EA201590621A1 (ru) | Ингибиторы аггреканазы | |
| PH12014500883A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| MX2015012629A (es) | Compuestos de imidazo piridina. | |
| ZA201301799B (en) | Process for the preparation of pan-cdk inhibitors of the formula (i),and intermediates of the preparation | |
| WO2013098833A3 (en) | Processes and intermediates for preparing rivaroxaban | |
| HUE066259T2 (hu) | Intermedierek a C-terminális HSP90 inhibitorok elõállításához | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| IN2015DN00598A (es) | ||
| CR20140306A (es) | Fluormetil -5,6-dihidro-4h-[1,3] oxazinas | |
| EP3057962A4 (en) | Hydrochloride salt form for ezh2 inhibition | |
| JO3318B1 (ar) | مثبطات bace | |
| PH12015500009A1 (en) | Phenoxyethyl piperidine compounds | |
| WO2014125506A3 (en) | A process for the preparation of ivacaftor and its intermediates | |
| IN2014DN07996A (es) | ||
| MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
| HK1205095A1 (en) | Methods and intermediates for preparing pharmaceutical agents | |
| MX337610B (es) | Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma. | |
| IN2013MU02010A (es) | ||
| IN2014MU00070A (es) | ||
| IN2013MU01524A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: ELANCO US INC. |
|
| FG | Grant or registration |